Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(40.0%)
Phase 2
2(40.0%)
N/A
1(20.0%)
5Total
Phase 4(2)
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07190261Phase 2Not Yet Recruiting

A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

Role: lead

NCT05399732Phase 2Completed

Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia

Role: lead

NCT06847607Not ApplicableNot Yet Recruiting

A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)

Role: lead

NCT04470804Phase 4Completed

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

Role: lead

NCT03364764Phase 4Completed

Sirolimus Treatment for Refractory PRCA

Role: lead

All 5 trials loaded